Animal models of the cancer anorexia-cachexia syndrome

被引:74
作者
Bennani-Baiti, Nabila [1 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Taussig Canc Ctr, Sect Palliat Med & Suppport Oncol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Taussig Canc Ctr, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44106 USA
关键词
Animal models; Cancer cachexia; Anorexia; Wasting; TUMOR-BEARING RATS; PROTEOLYSIS-INDUCING FACTOR; NECROSIS-FACTOR-ALPHA; LIPID-MOBILIZING FACTOR; GROWTH-FACTOR-I; WEIGHT-LOSS; SKELETAL-MUSCLE; THERAPEUTIC STRATEGIES; PROTEIN-TURNOVER; MESSENGER-RNA;
D O I
10.1007/s00520-010-0972-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aims Cancer cachexia, a complex wasting syndrome, is common in palliative medicine. Animal models expand our understanding of its mechanisms. A review of cancer cachexia and anorexia animal models will help investigators make an informed choice of the study model. Results and discussion Cancer-anorexia cachexia animal models are numerous. No one is ideal. The choice should depend on the research question. To investigate cancer-anorexia cachexia independent of pro-inflammatory cytokine effects, the MAC16 ADK and XK1 are useful. MAC16 ADK helps study the host's tumor metabolic effects, independent of any anorexia or inflammation. XK1 is both anorectic and cachectic, but data about it is limited. All other models induce a host inflammatory response. The Walker 256 ADK and MCG 101 are best avoided due to excessive tumor growth. Since individual models do not address all aspects of the syndrome, use of a combination seems wise. Suggested combinations: MAC16-ADK (non-inflammatory and non-anorectic) with YAH-130 (inflammatory, anorectic, and cachectic), Lewis lung carcinoma (slow onset anorexia) or prostate adenocarcinoma (inflammatory, anorectic but not cachectic) with YAH-130.
引用
收藏
页码:1451 / 1463
页数:13
相关论文
共 75 条
  • [61] Characterization of a cancer cachectic factor
    Todorov, P
    Cariuk, P
    McDevitt, T
    Coles, B
    Fearon, K
    Tisdale, M
    [J]. NATURE, 1996, 379 (6567) : 739 - 742
  • [62] Todorov PT, 1998, CANCER RES, V58, P2353
  • [63] Cancer cachexia and tumor growth reduction in Walker 256 tumor-bearing rats supplemented with N-3 polyunsaturated fatty acids for one generation
    Togni, V
    Ota, CCC
    Folador, A
    Tchaikovski, O
    Aikawa, J
    Yamazaki, RK
    Freitas, FA
    Longo, R
    Martins, EF
    Calder, PC
    Curi, R
    Fernandes, LC
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2003, 46 (01): : 52 - 58
  • [64] Interleukin-1β system in anorectic catabolic tumor-bearing rats
    Turrin, NP
    Ilyin, SE
    Gayle, DA
    Plata-Salamán, CR
    Ramos, EJB
    Laviano, A
    Das, UN
    Inui, A
    Meguid, MM
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2004, 7 (04) : 419 - 426
  • [65] Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia
    van der Worp, HB
    de Haan, P
    Morrema, E
    Kalkman, CJ
    [J]. JOURNAL OF NEUROLOGY, 2005, 252 (09) : 1108 - 1114
  • [66] Symptoms and prognosis in advanced cancer
    Walsh, D
    Rybicki, L
    Nelson, KA
    Donnelly, S
    [J]. SUPPORTIVE CARE IN CANCER, 2002, 10 (05) : 385 - 388
  • [67] The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients
    Walsh, D
    Donnelly, S
    Rybicki, L
    [J]. SUPPORTIVE CARE IN CANCER, 2000, 8 (03) : 175 - 179
  • [68] Watchorn TM, 2001, FASEB J, V15, P562
  • [69] The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer
    Williams, A
    Sun, XY
    Fischer, JE
    Hasselgren, PO
    [J]. SURGERY, 1999, 126 (04) : 744 - 749
  • [70] Role of cytokines in regulating feeding behaviour
    Wong, S
    Pinkney, J
    [J]. CURRENT DRUG TARGETS, 2004, 5 (03) : 251 - 263